Dianthus Therapeutics, Inc.

DNTH

US2528281080

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 2024-09-12			5-day change	1st Jan Change
27.81 ^USD	+0.87%		-0.61%	+167.40%

Aug. 09	Wedbush Adjusts Dianthus Therapeutics' PT to $36 From $38, Keeps Outperform Rating	MT
Aug. 08	Dianthus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell 3000E Growth Index

July 30, 2024

Latest news about Dianthus Therapeutics, Inc.

Wedbush Adjusts Dianthus Therapeutics' PT to $36 From $38, Keeps Outperform Rating	Aug. 09	MT
Dianthus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 08	CI
Baird Starts Dianthus Therapeutics With Outperform Rating, $58 Price Target	Jul. 26	MT
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell Small Cap Comp Value Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell Small Cap Completeness Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell Microcap Growth Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell 3000 Value Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell 2000 Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell 3000E Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell 2500 Value Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell Microcap Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell 2500 Growth Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell 3000E Growth Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell 3000 Growth Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell 2000 Value Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell 2000 Growth Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell 2000 Dynamic Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell Microcap Value Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell 3000E Value Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell 2500 Index	Jun. 30	CI
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell 3000 Index	Jun. 30	CI
Cantor Fitzgerald Initiates Dianthus Therapeutics at Overweight	Jun. 27	MT
Dianthus Therapeutics Secures US FDA Approval to Launch Phase 2 Study of DNTH103 in Multifocal Motor Neuropathy	Jun. 12	MT
Dianthus Therapeutics Gets FDA Clearance for DNTH103 Phase 2 Trial	Jun. 12	DJ

Chart Dianthus Therapeutics, Inc.

Duration

Period

More charts

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile.

Employees

Sector

Biotechnology & Medical Research

Calendar

2024-09-17 - Cantor Global Healthcare Conference

More about the company